The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2020 | Novel antibodies in AML
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, outlines novel antibody-based immunotherapies developed for the treatment of acute myeloid leukemia (AML), as well as challenges with implementing these agents. Prof. Subklewe also discusses the development of gemtuzumab, the only antibody-drug conjugate approved for the treatment of AML as well as checkpoint inhibitors such as nivolumab, that have been investigated in monotherapy and combination in this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
